Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Dr Neeraj Agarwal, including the following topics:
- Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)
- Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)
- Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)
- Managing treatment-related adverse events from capivasertib (20:08)
- Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)
- Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)
CME information and select publications
